Phoenix Molecular Designs is a biopharmaceutical company developing precise cancer therapeutics and companion diagnostics by targeting kinases. The company is focused on first-in-class inhibitors against ribosomal S6 kinase (RSK) and its lead asset is PMD-026, which disrupts activated RSK2. PhoenixMD plans to use the financing to advance PMD-026 through IND-enabling studies and to develop a companion diagnostic to identify patients with high levels of activated RSK2. The company completed a $2.7M financing comprising an oversubscribed $2.0M venture round and over $670K in non-dilutive capital. The venture round was led by Pallasite Ventures and included participation from new and existing angel investors. PhoenixMD is led by CEO Sandra E. Dunn, Ph.D., has operations in Vancouver and U.S. operations in San Diego, and has partnerships with the National Cancer Institute, University of Florida, Kyushu University, Mayo Clinic, and the University of Hawaii Comprehensive Cancer Center.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2018